Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 49


Circulating cell-free DNA in breast cancer: size profiling, levels, and methylation patterns lead to prognostic and predictive classifiers.

Panagopoulou M, Karaglani M, Balgkouranidou I, Biziota E, Koukaki T, Karamitrousis E, Nena E, Tsamardinos I, Kolios G, Lianidou E, Kakolyris S, Chatzaki E.

Oncogene. 2019 Jan 14. doi: 10.1038/s41388-018-0660-y. [Epub ahead of print]


Liquid biopsies.

Lianidou E, Pantel K.

Genes Chromosomes Cancer. 2019 Apr;58(4):219-232. doi: 10.1002/gcc.22695. Review.


A pilot plasma-ctDNA ring trial for the Cobas® EGFR Mutation Test in clinical diagnostic laboratories.

Ntzifa A, Kroupis C, Haliassos A, Lianidou E.

Clin Chem Lab Med. 2018 Sep 29. pii: /j/cclm.ahead-of-print/cclm-2018-0676/cclm-2018-0676.xml. doi: 10.1515/cclm-2018-0676. [Epub ahead of print] No abstract available.


Evaluation of Preanalytical Conditions and Implementation of Quality Control Steps for Reliable Gene Expression and DNA Methylation Analyses in Liquid Biopsies.

Zavridou M, Mastoraki S, Strati A, Tzanikou E, Chimonidou M, Lianidou E.

Clin Chem. 2018 Oct;64(10):1522-1533. doi: 10.1373/clinchem.2018.292318. Epub 2018 Jul 17.


ESR1 Methylation: A Liquid Biopsy-Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment.

Mastoraki S, Strati A, Tzanikou E, Chimonidou M, Politaki E, Voutsina A, Psyrri A, Georgoulias V, Lianidou E.

Clin Cancer Res. 2018 Mar 15;24(6):1500-1510. doi: 10.1158/1078-0432.CCR-17-1181. Epub 2017 Dec 28.


A Comparison of Three Methods for the Detection of Circulating Tumor Cells in Patients with Early and Metastatic Breast Cancer.

Politaki E, Agelaki S, Apostolaki S, Hatzidaki D, Strati A, Koinis F, Perraki M, Saloustrou G, Stoupis G, Kallergi G, Spiliotaki M, Skaltsi T, Lianidou E, Georgoulias V, Mavroudis D.

Cell Physiol Biochem. 2017;44(2):594-606. doi: 10.1159/000485115. Epub 2017 Nov 20.


Direct comparison study of DNA methylation markers in EpCAM-positive circulating tumour cells, corresponding circulating tumour DNA, and paired primary tumours in breast cancer.

Chimonidou M, Strati A, Malamos N, Kouneli S, Georgoulias V, Lianidou E.

Oncotarget. 2017 Jun 27;8(42):72054-72068. doi: 10.18632/oncotarget.18679. eCollection 2017 Sep 22.


Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma.

Strati A, Koutsodontis G, Papaxoinis G, Angelidis I, Zavridou M, Economopoulou P, Kotsantis I, Avgeris M, Mazel M, Perisanidis C, Sasaki C, Alix-Panabières C, Lianidou E, Psyrri A.

Ann Oncol. 2017 Aug 1;28(8):1923-1933. doi: 10.1093/annonc/mdx206.


Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients.

Kuske A, Gorges TM, Tennstedt P, Tiebel AK, Pompe R, Preißer F, Prues S, Mazel M, Markou A, Lianidou E, Peine S, Alix-Panabières C, Riethdorf S, Beyer B, Schlomm T, Pantel K.

Sci Rep. 2016 Dec 21;6:39736. doi: 10.1038/srep39736.


Methylation status of the APC and RASSF1A promoter in cell-free circulating DNA and its prognostic role in patients with colorectal cancer.

Matthaios D, Balgkouranidou I, Karayiannakis A, Bolanaki H, Xenidis N, Amarantidis K, Chelis L, Romanidis K, Chatzaki A, Lianidou E, Trypsianis G, Kakolyris S.

Oncol Lett. 2016 Jul;12(1):748-756. Epub 2016 Jun 1.


Direct Comparison of Metastasis-Related miRNAs Expression Levels in Circulating Tumor Cells, Corresponding Plasma, and Primary Tumors of Breast Cancer Patients.

Markou A, Zavridou M, Sourvinou I, Yousef G, Kounelis S, Malamos N, Georgoulias V, Lianidou E.

Clin Chem. 2016 Jul;62(7):1002-11. doi: 10.1373/clinchem.2015.253716. Epub 2016 May 19.


MicroRNA-194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma.

Nofech-Mozes R, Khella HW, Scorilas A, Youssef L, Krylov SN, Lianidou E, Sidiropoulos KG, Gabril M, Evans A, Yousef GM.

Cancer Med. 2016 Apr;5(4):656-64. doi: 10.1002/cam4.631. Epub 2016 Feb 10.


SOX17 promoter methylation in plasma circulating tumor DNA of patients with non-small cell lung cancer.

Balgkouranidou I, Chimonidou M, Milaki G, Tsaroucha E, Kakolyris S, Georgoulias V, Lianidou E.

Clin Chem Lab Med. 2016 Aug 1;54(8):1385-93. doi: 10.1515/cclm-2015-0776.


Development of a novel PTT assay for mutation detection in PALB2 large exons and PALB2 screening in medullary breast cancer.

Poumpouridou N, Goutas N, Tsionou C, Dimas K, Lianidou E, Kroupis C.

Fam Cancer. 2016 Apr;15(2):183-91. doi: 10.1007/s10689-015-9851-7.


Development and validation of molecular methodologies to assess PALB2 expression in sporadic breast cancer.

Poumpouridou N, Acha-Sagredo A, Goutas N, Vlachodimitropoulos D, Chatziioannidou I, Lianidou E, Liloglou T, Kroupis C.

Clin Biochem. 2016 Feb;49(3):253-9. doi: 10.1016/j.clinbiochem.2015.10.009. Epub 2015 Oct 23.


miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma.

Khella HWZ, Butz H, Ding Q, Rotondo F, Evans KR, Kupchak P, Dharsee M, Latif A, Pasic MD, Lianidou E, Bjarnason GA, Yousef GM.

Mol Ther. 2015 Nov;23(11):1748-1758. doi: 10.1038/mt.2015.129. Epub 2015 Jul 23.


An integrated genomic analysis of papillary renal cell carcinoma type 1 uncovers the role of focal adhesion and extracellular matrix pathways.

Wala SJ, Karamchandani JR, Saleeb R, Evans A, Ding Q, Ibrahim R, Jewett M, Pasic M, Finelli A, Pace K, Lianidou E, Yousef GM.

Mol Oncol. 2015 Oct;9(8):1667-77. doi: 10.1016/j.molonc.2015.04.007. Epub 2015 May 14.


A rapid and accurate closed-tube Methylation-Sensitive High Resolution Melting Analysis assay for the semi-quantitative determination of SOX17 promoter methylation in clinical samples.

Mastoraki S, Chimonidou M, Dimitrakopoulos L, Kounelis S, Malamos N, Georgoulias V, Lianidou E.

Clin Chim Acta. 2015 Apr 15;444:303-9. doi: 10.1016/j.cca.2015.02.035. Epub 2015 Feb 27.


Metastasis-related miRNAs: a new way to differentiate patients with higher risk?

Markou A, Lianidou E, Georgoulias V.

Future Oncol. 2015;11(3):365-7. doi: 10.2217/fon.14.294. No abstract available.


Low expression of miR-126 is a prognostic marker for metastatic clear cell renal cell carcinoma.

Khella HW, Scorilas A, Mozes R, Mirham L, Lianidou E, Krylov SN, Lee JY, Ordon M, Stewart R, Jewett MA, Yousef GM.

Am J Pathol. 2015 Mar;185(3):693-703. doi: 10.1016/j.ajpath.2014.11.017. Epub 2015 Jan 5.


Supplemental Content

Loading ...
Support Center